Liminal BioSciences Inc. (LMNL)
Stock Price:
$12.49 USD
-0.38 (-2.95%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Pre-market: $12.50 +0.01 (0.08%) Jul 10, 5:54 PM
Key Info
| Market Cap |
292.52M |
| Revenue (ttm) |
3.74M |
| Net Income (ttm) |
-158.62M |
| Shares Out |
23.42M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$12.49 |
| Previous Close |
$12.87 |
| Change ($) |
-0.38 |
| Change (%) |
-2.95% |
| Day's Open |
12.76 |
| Day's Range |
12.15 - 13.00 |
| Day's Volume |
28,932 |
| 52-Week Range |
7.33 - 31.45 |
More Stats
| Market Cap |
292.52M |
| Enterprise Value |
281.67M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.42M |
| Float |
3.38M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-4.94 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
40,829 |
| Short Ratio |
2.31 |
| Short % of Float |
1.21% |
| Beta |
1.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
78.14 |
| PB Ratio |
2.99 |
| Revenue |
3.74M |
| Operating Income |
-99.71M |
| Net Income |
-158.62M |
| Free Cash Flow |
-79.26M |
| Net Cash |
10.85M |
| Net Cash / Share |
0.47 |
| Gross Margin |
43.66% |
| Operating Margin |
-2,663.58% |
| Profit Margin |
-4,237.30% |
| FCF Margin |
-2,117.33% |
| ROA |
-55.46% |
| ROE |
-390.87% |
| ROIC |
-141.90% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions CAD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 4.90 | 24.63 | 22.31 |
| Revenue Growth | -80.09% | 10.4% | - |
| Gross Profit | 2.14 | -1.07 | 18.62 |
| Operating Income | -131 | -265 | -125 |
| Net Income | -208 | -280 | -130 |
| Shares Outstanding | 16.06 | 0.83 | 0.80 |
| Earnings Per Share | -12.81 | -235.95 | -137.85 |
| Operating Cash Flow | -99.39 | -82.45 | -123 |
| Capital Expenditures | -4.44 | -5.13 | -10.08 |
| Free Cash Flow | -104 | -87.58 | -133 |
| Cash & Equivalents | 61.29 | 7.39 | 38.87 |
| Total Debt | 47.07 | 128 | 49.12 |
| Net Cash / Debt | 14.21 | -120 | -10.25 |
| Assets | 165 | 103 | 265 |
| Liabilities | 70.16 | 166 | 106 |
| Book Value | 102 | -56.60 | 132 |
Numbers in millions CAD, except per-share numbers.
Company Details
| Full Name |
Liminal BioSciences Inc. |
| Country |
Canada |
| Employees |
300 |
| CEO |
Kenneth Harry Galbraith |
Stock Information
| Ticker Symbol |
LMNL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LMNL |
Description
Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.